Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 846 results for "novartis ag"

Novartis, Pfizer seek U.S. approval of meningitis vaccines
Reuters

Novartis malaria drug candidate delivers encouraging results

13:04 ET | About: Novartis AG (NVS) In a just-published article detailing clinical trial results for Novartis' (NVS -1.2%) antimalarial drug candidate, KAE609 (cipargamin), the parasite was cleared in adult patients in a median time of only 12 ... Seeking Alpha, 6 hours ago
[x]  

104 images for novartis ag

4 Traders, 2 days ago
KansasCity.com, 2 weeks ago
Miami Herald, 2 weeks ago
Time, 2 weeks ago
BioSpace, 6 days ago
BusinessWeek, 2 weeks ago
BusinessWeek, 2 weeks ago
Boston Globe, 3 weeks ago
FinanzNachrichten.de, 1 day ago
Deseret Morning News, 2 weeks ago
Reuters UK

Novartis apologises for hiding side-effects of leukaemia drugs

TOKYO: The Japanese unit of Novartis AG apologised on Thursday for nfailing to report to authorities in a timely manner side-effects of its leukaemia drugs, in the company's latest scandal in the country. Novartis Pharma KK, the Swiss drugmaker's ...
 Economic Times12 hours ago UPDATE 1-Novartis apologises for not disclosing side-effects of leukaemia drugs sooner  Reuters13 hours ago Novartis deeply regrets not reporting serious side effects of leukemia treatments sooner  MedCity News9 hours ago Novartis apologises for not disclosing side-effects of leukaemia drugs sooner  Economic Times12 hours ago
[x]  
Jagran Post

Novartis India Q1 net up 3% at Rs 14.31 cr

Drug firm Novartis India today reported a 3.17% rise in its standalone net profit to Rs 14.31 crore for the quarter ended June 30, 2014. The company had posted a net profit of Rs 13.87 crore for the corresponding period of the previous fiscal, ...
 Business Standard India6 days ago Novartis India net sales plunge by 8% in Q1  PharmaBiz6 days ago Novartis India Q1 Net Up 3 Per Cent at Rs 14.31 Crore  NDTV6 days ago Novartis India Q1 net profit up 3% at Rs 14.31 crore  Economic Times6 days ago
[x]  
Sify

Ranbaxy up; nod to generic version of Novartis drug

Ranbaxy Laboratories rose 5.8 percent in early trading after the U.S. Food and Drug Administration said on Thursday it had approved the company's generic version of Novartis AG's blood pressure drug Diovan. Investors say current market size of Diovan in the ...
 Sify1 month ago India's Ranbaxy gains; U.S. drug regulator approves generic version of Novartis drug  Reuters1 month ago Sun Pharma settles Novartis lawsuit over drug Gleevec  Money Control2 months ago More pharma firms trying to settle patent rows via talks  Livemint.com2 days ago
[x]  
Reuters

Ranbaxy gets FDA nod for Novartis generic pill

Ranbaxy Laboratories Ltd has received approval from the US Food and Drug Administration to launch a cheaper copy of Novartis AG's blood pressure pill Diovan, bolstering its outlook after a raft of regulatory bans for poor production quality at its India ...
 Times of India1 month ago Ranbaxy gets FDA approval for Novartis's Diovan generic  Reuters1 month ago India's Ranbaxy gets FDA approval for Novartis's Diovan generic  Reuters1 month ago
[x]  
Scottrade

Global Parkinson's Disease Market 2014-2018: Key Vendors are Boehringer Ingelheim, GlaxoSmithKline, Novartis and Teva

/PRNewswire/ -- Research and Markets has announced the addition of the "Global Parkinson's Disease Market 2014-2018" report to their offering. http://photos.prnewswire.com/prnh/20130307/600769 Parkinson's disease is a progressive ...
 PR Newswire9 hours ago Global Retinal Vein Occlusion Market 2014-2018: Key Vendors are Bayer, F. Hoffmann-La Roche, Novartis and Regeneron Pharmaceuticals  Sys-Con India1 day ago Research and Markets: Global Retinal Vein Occlusion Market 2014-2018: Key Vendors are Bayer, F. Hoffmann-La Roche, Novartis and Regeneron Pharmaceuticals  TMC Net1 day ago RESEARCH AND MARKETS : Global Retinal Vein Occlusion Market 2014-2018: Key Vendors are Bayer, F. Hoffmann-La Roche, Novartis and Regeneron Pharmaceuticals  4 Traders1 day ago
[x]  

Novartis vaccine Bexsero® sees high uptake in first large-scale public vaccination program to help protect against devastating meningitis B

World News: 06:15 GMT Tuesday 29th July 2014 . [ Novartis International AG via Thomson Reuters ONE via SPi World News ] This story Novartis International AG / Novartis vaccine Bexsero® sees high uptake in first large-scale public ...
 SPi World News2 days ago KAE609 shows promise as next generation treatment for malaria  Reuters1 day ago NOVARTIS : KAE609 shows promise as next generation treatment for malaria »  4 Traders17 hours ago Novartis vaccine Bexsero(R) sees high uptake in first large-scale public vaccination program to help protect against devastating meningitis B  Individual.com2 days ago
[x]  

Japan ministry tells Novartis to improve practices over leukaemia drug -Jiji

The Japanese unit of Novartis AG was told by the health ministry to improve its business practices for not reporting side-effects of a leukaemia drug, Jiji news agency reported on Thursday. TOKYO, July 31 The Ministry of Health, Labour and Welfare ...
 Reuters16 hours ago

Novartis Malaria Pill Shows Promise as Best Drugs Fail

Efforts to develop the first new malaria treatment in 20 years advanced as a pill from Novartis AG (NOVN) cleared parasites faster than the best medicines, potentially providing a solution to the spread of drug resistance. In a study among 21 ...
 BusinessWeek1 day ago

Novartis AG (NVS) Trading Near $89.02 Resistance Level

%ccnetdebit% net debit. This trade has an assigned return of 2.15% but the downside protection increases to 3.11%. Standard & PooraEUR(TM)s has a 4 STARS (out of 5) buy ranking and a 12-month target price of $99.00 on Novartis AG. Over the last 52 ...
 Individual.com3 days ago Novartis AG (NVS) Trading Near $88.99 Resistance Level  Individual.com8 hours ago Novartis AG (NVS) Showing Support Near $88.07  Individual.com1 week ago Novartis AG (NVS) Showing Bearish Technicals With Support At $88.72  Individual.com1 week ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less